Pharmacyte Biotech (PMCB) closed at $0.40 on November 12, 2026, up 0.8% from the previous close, on volume of 379,761 shares (30-day average 142,597).
Data as of November 12, 2026.
PharmaCyte Biotech approves 1-for-19 reverse stock split for Nasdaq compliance
Seeking Alpha News (Wed, 11-Nov 9:17 AM ET)
PharmaCyte Biotech, Inc. Announces Reverse Stock Split
Business Wire (Wed, 11-Nov 9:00 AM ET)
PharmaCyte Biotech Boosts Cash Reserves to $20 Million with Femasys Stake Monetization
Market Chameleon (Tue, 25-Nov 6:06 AM ET)
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.
Pharmacyte Biotech trades on the NASDAQ stock market under the symbol PMCB.
As of November 12, 2026, PMCB stock price was flat at $0.40 with 379,761 million shares trading.
PMCB has a beta of 1.38, meaning it tends to be more sensitive to market movements. PMCB has a correlation of 0.04 to the broad based SPY ETF.
PMCB has a market cap of $4.32 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, PMCB traded as high as $2.58 and as low as $.25.
The top ETF exchange traded funds that PMCB belongs to (by Net Assets): VXF.
PMCB has underperformed the market in the last year with a return of -54.2%, while the SPY ETF gained +12.0%. In the last 3 month period, PMCB fell short of the market, returning -26.9%, while SPY returned -1.5%. However, in the most recent 2 weeks PMCB has outperformed the stock market by returning +20.1%, while SPY returned -2.0%.
PMCB support price is $.35 and resistance is $.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PMCB shares will trade within this expected range on the day.
